We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: oncology
MedXY News
EnglishTag

oncology

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Long-Term Survival Outweighs Short-Term Quality of Life: Why Esophagectomy Remains the Gold Standard for Esophageal Cancer Responders
General Surgeryactive surveillanceEsophagectomy

Long-Term Survival Outweighs Short-Term Quality of Life: Why Esophagectomy Remains the Gold Standard for Esophageal Cancer Responders

By MedXY|Mar 13, 2026

A decision analytical model reveals that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy provides superior 5-year survival and quality-adjusted life-years (QALYs) for esophageal cancer patients a

Lymph Node Isolated Tumor Cells in Ovarian Cancer: Clinically Significant or Pathological Incidentaloma?
newsDi căn hạch cổIsolated Tumor Cells

Lymph Node Isolated Tumor Cells in Ovarian Cancer: Clinically Significant or Pathological Incidentaloma?

By MedXY|Mar 13, 2026

A large-scale cohort study of over 15,000 patients reveals that isolated tumor cells (ITCs) in regional lymph nodes do not significantly impact short-term overall survival in epithelial ovarian cancer, despite higher prevalence in low-grade

Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy
newshormone therapyoncology

Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy

By MedXY|Mar 6, 2026

A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standa

The TIP-CA Model: A Validated Tool to Stratify Cancer Risk in Adult Dermatomyositis Patients
DermatologyDermatomyositisoncology

The TIP-CA Model: A Validated Tool to Stratify Cancer Risk in Adult Dermatomyositis Patients

By MedXY|Mar 4, 2026

Researchers have developed and validated the TIP-CA model, a clinical tool using five key factors—anti-TIF1-γ, ILD absence, poikiloderma, DM subtype, and anemia—to accurately predict malignancy risk in patients with dermatomyositis, enablin

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers
GastroenterologyIrinotecanoncology

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers

By MedXY|Mar 4, 2026

A multicentre cohort study confirms that upfront 30% irinotecan dose reductions for UGT1A1 poor metabolisers effectively prevent severe toxicity without compromising progression-free or overall survival in colorectal and pancreatic cancer p

Adjunctive Ultrasonography Reduces Advanced Breast Cancer Risk in Women Aged 40-49: Long-Term Evidence from J-START
newsbreast cancer screeningoncology

Adjunctive Ultrasonography Reduces Advanced Breast Cancer Risk in Women Aged 40-49: Long-Term Evidence from J-START

By MedXY|Mar 2, 2026

A prespecified secondary analysis of the J-START trial reveals that adding ultrasonography to mammography for women aged 40-49 significantly reduces the long-term cumulative incidence of advanced breast cancer, particularly in populations w

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
newsenfortumab vedotinoncology

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

By MedXY|Feb 22, 2026

The Phase 3 KEYNOTE-905/EV-303 trial demonstrates that perioperative enfortumab vedotin plus pembrolizumab significantly improves event-free survival (HR 0.40) and overall survival (HR 0.50) compared to surgery alone in cisplatin-ineligible

Optimizing Prognosis: The New AJCC Version 9 Staging for Salivary Gland Carcinoma
newsoncologySalivary Gland Carcinoma

Optimizing Prognosis: The New AJCC Version 9 Staging for Salivary Gland Carcinoma

By MedXY|Feb 20, 2026

The proposed AJCC/UICC Version 9 staging for salivary gland carcinoma shifts toward a unified, specific system using lymph node count and extranodal extension, significantly improving prognostic accuracy for both major and minor salivary gl

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice
newsadverse eventshead and neck cancer

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

By MedXY|Feb 19, 2026

A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer
newsbreast cancerCDK4/6 inhibitors

Timing the Tactic: SONIA Trial Finds No Survival Advantage for First-Line vs. Second-Line CDK4/6 Inhibition in Advanced Breast Cancer

By MedXY|Feb 19, 2026

The phase 3 SONIA trial demonstrates that initiating CDK4/6 inhibitors in the first-line setting does not improve overall survival compared to second-line use in HR-positive, ERBB2-negative advanced breast cancer, while significantly increa

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial
newsadjuvant therapyAumolertinib

Aumolertinib Transforms Adjuvant Treatment for EGFR-Mutated Lung Cancer: Significant Survival Gains in the Phase 3 ARTS Trial

By MedXY|Feb 19, 2026

The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials
Hematology-Oncologyclinical trialsoncology

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

By MedXY|Feb 18, 2026

A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i

Breaking the Cycle of Exclusion: How Cultural Capital and Stigma Hinder Hospice Access for Low-Income Patients
newshealth equityoncology

Breaking the Cycle of Exclusion: How Cultural Capital and Stigma Hinder Hospice Access for Low-Income Patients

By MedXY|Feb 10, 2026

A qualitative study published in JAMA Network Open identifies how limited cultural capital, cancer-related stigma, and economic deprivation form a self-reinforcing cycle that excludes low-income patients from hospice care, highlighting the

Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer
newsDocetaxelmCRPC

Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer

By MedXY|Feb 9, 2026

A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to d

Opportunistic Bilateral Salpingectomy Reduces Serous Ovarian Cancer Risk by Nearly 80 Percent
newsoncologyovarian cancer

Opportunistic Bilateral Salpingectomy Reduces Serous Ovarian Cancer Risk by Nearly 80 Percent

By MedXY|Feb 9, 2026

A large-scale population study confirms that removing fallopian tubes during unrelated pelvic surgeries reduces serous ovarian cancer risk by 78%, providing robust evidence for its use as a primary prevention strategy against high-grade ser

Beyond the Bill: Hope and Social Support as Vital Buffers Against Cancer-Related Financial Toxicity
newsfinancial toxicityoncology

Beyond the Bill: Hope and Social Support as Vital Buffers Against Cancer-Related Financial Toxicity

By MedXY|Feb 9, 2026

A multisite study reveals that financial toxicity significantly reduces life satisfaction in cancer patients. However, hopefulness and social support act as critical mediators, suggesting that integrating psychosocial resilience training wi

Pandemic Care Disruptions Linked to Significant Decline in Short-Term Cancer Survival and 17,000 Excess Deaths
newsCancer survivalCOVID-19 pandemic

Pandemic Care Disruptions Linked to Significant Decline in Short-Term Cancer Survival and 17,000 Excess Deaths

By MedXY|Feb 9, 2026

A population-based cohort study using SEER-21 data reveals that patients diagnosed with cancer during 2020 and 2021 experienced significantly lower 1-year cause-specific survival rates compared to prepandemic trends, resulting in an estimat

Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns
newsCancer survivaloncology

Mapping the European Cancer Landscape: A 1.7 Million Patient Study Reveals Survival Gaps and Comorbidity Patterns

By MedXY|Feb 7, 2026

A large-scale federated study of 1.7 million European patients highlights significant variations in cancer survival and comorbidity profiles, emphasizing the role of real-world data and the OMOP-CDM framework in benchmarking oncological out

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk
newsMenopauseoncology

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk

By MedXY|Feb 6, 2026

A massive cohort study of 2.2 million women reveals that ovarian cancer risk factors vary significantly by menopausal status and birth year. While early menarche and low parity remain universal risks, the protective benefits of breastfeedin

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window
Diabetes & Endocrinologynew-onset diabetesoncology

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window

By MedXY|Feb 4, 2026

A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.

Prev
2 / 5
12345
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities